Table 1 Observed versus simulated patient response rates to epcoritamab, mosunetuzumab, and loncastuximab-riensine monotherapy treatments

From: QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy